BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BridgeBio Pharma (Nasdaq: BBIO), a biopharmaceutical company focused on genetic diseases, has announced several inducement grants of restricted stock units (RSUs) to new employees. The compensation committee approved RSU grants totaling 238,168 shares across 74 new employees between June and September 2025.
The RSU grants follow a consistent vesting schedule, with 25% of shares vesting after one year and the remaining shares vesting quarterly over the following three years, contingent on continued employment. These grants were made under the Company's Amended and Restated 2019 Inducement Equity Plan.
Details
News Market Reaction – BBIO
On Sep 11, the first trading day after this news, BBIO closed 0.68% below the previous close.
Data tracked by StockTitan Argus for the Sep 11 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PALO ALTO, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that the compensation committee of its board of directors (the “committee”) approved equity grants in the form of restricted stock units (“RSUs”) to new employees under the Company’s Amended and Restated 2019 Inducement Equity Plan (the “Plan”). The committee approved: (i) on September 5, 2025, RSU grants covering an aggregate of 33,684 shares of the Company’s common stock to 13 new employees; (ii) on August 4, 2025, RSU grants covering an aggregate of 32,145 shares of the Company’s common stock to 16 new employees; and (iii) on July 14, 2025, RSU grants covering an aggregate of 73,991 shares of the Company’s common stock to 20 new employees. One-fourth of the shares underlying these RSUs will vest on August 16, 2026, with the remaining shares vesting in equal quarterly installments over the following three years, subject to continued employment with BridgeBio or its subsidiaries on each applicable vesting date. Separately, on June 6, 2025, the committee approved RSU grants covering an aggregate of 98,348 shares of the Company’s common stock to 25 new employees, with one-fourth of the shares vesting on May 16, 2026, and the balance vesting in equal quarterly installments over the following three years, also subject to continued employment with BridgeBio or its subsidiaries on each applicable vesting date.
All of the above-described awards were made under the Plan.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter, Facebook, Instagram, and YouTube.
BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
contact@bridgebio.com
(650)-789-8220
BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.